Carla Ijurko
Overview
Explore the profile of Carla Ijurko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ijurko C, Romo-Gonzalez M, Prieto-Bermejo R, Diez-Campelo M, Vidriales M, Muntion S, et al.
Biomark Res
. 2024 Oct;
12(1):128.
PMID: 39468687
Acute myeloid leukaemia (AML) is a highly heterogeneous malignancy, with a poor 5-year overall survival rate of approximately 30%. Consequently, the search for novel therapeutic strategies is ongoing, and the...
2.
Ijurko C, Romo-Gonzalez M, Garcia-Calvo C, Sardina J, Sanchez-Bernal C, Sanchez-Yague J, et al.
Free Radic Biol Med
. 2023 Oct;
209(Pt 1):18-28.
PMID: 37806599
Acute myeloid leukaemia (AML) is a highly heterogeneous disease, however the therapeutic approaches have hardly changed in the last decades. Metabolism rewiring and the enhanced production of reactive oxygen species...
3.
Romo-Gonzalez M, Ijurko C, Alonso M, Gomez de Cedron M, Ramirez de Molina A, Soriano M, et al.
Free Radic Biol Med
. 2023 Feb;
198:92-108.
PMID: 36764627
Cancer cells are characterised by an elevated metabolic plasticity and enhanced production of reactive oxygen species (ROS), two features acknowledged as hallmarks in cancer, with a high translational potential to...
4.
Romo-Gonzalez M, Ijurko C, Hernandez-Hernandez A
Front Immunol
. 2022 Jun;
13:889875.
PMID: 35757686
Reactive oxygen species (ROS), previously considered toxic by-products of aerobic metabolism, are increasingly recognized as regulators of cellular signaling. Keeping ROS levels low is essential to safeguard the self-renewal capacity...
5.
A 29-gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival
Ijurko C, Gonzalez-Garcia N, Galindo-Villardon P, Hernandez-Hernandez A
Am J Hematol
. 2022 Jan;
97(4):448-457.
PMID: 35073432
The molecular complexity displayed in acute myeloid leukemia (AML) hinders patient stratification and treatment decisions. Previous studies support the utility of using specific gene panels for this purpose. Focusing on...
6.
Perez-Fernandez A, Lopez-Ruano G, Prieto-Bermejo R, Ijurko C, Diez-Campelo M, Sanchez-Guijo F, et al.
J Exp Clin Cancer Res
. 2019 Feb;
38(1):80.
PMID: 30764849
Background: The differentiation-based therapy for acute promyelocytic leukemia (APL) is an inspiring example for the search of novel strategies aimed at treatment of other subtypes of acute myeloid leukemia (AML)....
7.
Prieto-Bermejo R, Romo-Gonzalez M, Perez-Fernandez A, Ijurko C, Hernandez-Hernandez A
J Exp Clin Cancer Res
. 2018 Jun;
37(1):125.
PMID: 29940987
Oxidative stress is related to ageing and degenerative diseases, including cancer. However, a moderate amount of reactive oxygen species (ROS) is required for the regulation of cellular signalling and gene...